Invitrogen has created three new business divisions in a move to
strengthen its position in the growing biotechnology industry and
drive growth through improving links between its product
development cycle and customer base.
Accelovance has broadened its presence in China and expanded its
capacity for conducting Phase I-IV clinical trials for Western
pharmaceutical and biotech firms seeking to enter the Chinese
market, by opening a new office in Shanghai.
Private equity firm, Direct Capital has acquired a shareholding of
51 per cent in New Zealand Pharmaceuticals (NZP). The investment by
Direct Capital aims to tap into the growing potential of
The Pharmaceutical Fine Chemicals Business of Clariant took the
opportunity to review new developments at the CPhI Expo in Madrid,
Spain, making announcements on new investments in facilities in
Europe and the US as well as new business...
Pliva released its financial results for the first nine months of
2005, which revealed a net loss of $34 million, as the drug maker
tries to recover from its loss-making drug launch in the US. This
is despite posting higher revenues...
Dr. Reddy's Laboratories (DRL) has signed a definitive agreement to
acquire Roche's Mexican API business, in a move to drive the next
wave of growth in its custom pharmaceutical services (CPS)
New findings may have significant implications for the growing
generics drugs industry, by challenging previous assumptions that
all formulations of the same active pharmaceutical ingredient (API)
are therapeutically equivalent.
AssurX have launched a software process for document control, which
will enable pharmaceutical manufacturing companies to streamline
their approach to monitoring safety issues and overall quality